Satsuma Pharmaceuticals, Inc. (STSA)

$4.32

+0.18 (+4.35%)
Rating:
Recommendation:
-
Symbol STSA
Price $4.32
Beta 1.043
Volume Avg. 0.06M
Market Cap 136.277M
Shares () -
52 Week Range 2.51-7.46
1y Target Est -
DCF Unlevered STSA DCF ->
DCF Levered STSA LDCF ->
ROE -37.70% Strong Sell
ROA -43.44% Strong Sell
Operating Margin -
Debt / Equity 7.69% Neutral
P/E -
P/B 1.57 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest STSA news


Mr. John Kollins
Healthcare
Biotechnology
NASDAQ Global Market

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.